Latest News
All Times Eastern
- Will the ECB hike rates or not? Decision set to be cliff hanger as eurozone sentiment indicators deteriorate
- DocuSign shares rise after earnings, and other movers
- Barron's DocuSign, Apple, Smartsheet, Guidewire Software, RH, and More Stock Market Movers
- U.S. stock futures lean higher after difficult week on Wall Street
- Barron's Banks Are Stuck in a Rut. A Buyout Wave Could Be Building.
- Barron's High-Quality Dividend Stocks Are on Sale. Now Is the Time to Buy.
- Barron's Why Walt Disney Could Cave First in Its Cable Standoff With Charter
- Barron's 5 Federal Deficit Myths, Explained
- Barron's Walgreens Is Looking for a New CEO. Why That Could Make the Stock a Winner.
- Barron's Active Funds Rocked August. Passive Is Grabbing the Year.
to be replaced
Royalty Pharma PLC
RPRXUS
$
0.00
-0.03%
After Hours
$
28.85
After Hours Volume:
101.26K
| Close | Chg | Chg % |
|---|---|---|
| $28.86 | -0.21 | -0.72% |
Volume: 5.28M
65 Day Avg: 2.31M
28.46
Day Range
29.11
28.46
52 Week Range
44.47
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
RPRX Overview
Key Data
- Open $29.03
- Day Range 28.46 - 29.11
- 52 Week Range 28.46 - 44.47
- Market Cap $17.49B
- Shares Outstanding 448.93M
- Public Float 377.83M
- Beta 0.64
- Rev. per Employee $31.489M
- P/E Ratio 51.08
- EPS $0.57
- Yield 2.77%
- Dividend $0.20
- Ex-Dividend Date Aug 17, 2023
- Short Interest 9.36M 08/15/23
- % of Float Shorted 2.48%
- Average Volume 2.31M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 8
Full Ratings
Recent News
Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln
Royalty Pharma Plc said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. . The royalties include Ionis' interests in Biogen's Spinraza (nusinersen) medicine and Novartis...
Deal includes interest in Ionis' royalty in Biogen's Spinraza and Novartis' pelacarsen
Royalty Pharma acquires interest in Ionis royalties for $1.125 bln
Theravance sets up deal to sell rights to asthma drug to Royalty Pharma
Shares of Theravance Biopharma Inc. were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's Trelegy Ellipta to Royalty Pharma for $1.1 bi...
Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion
Shares of Blueprint Medicines Corp. gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma , which acquires pharmaceutical royalties, worth up ...
Royalty Pharma upgraded to overweight from neutral at J.P. Morgan
Biotech and Pharma MorphoSys Fell Too Far After M&A News, Analyst Says
Biotech and Pharma MorphoSys Buys Constellation Pharma in $1.7B Deal. Is Biotech M&A Back?
Royalty Pharma increases quarterly dividend by 13% to 17 cents a share
Royalty Pharma plc said Friday its board has approved a 13% increase in its quarterly dividend to 17 cents a share. The dividend will be paid March 15 to shareholders of record as of Feb. 19. Shares of the company, a buye...
Royalty Pharma increases quarterly dividend by 13% to 17 cents a share
Royalty Pharma upgraded to buy from neutral at UBS
Royalty Pharma prices $6 billion bond deal that is its first as a public company
Royalty Pharma PLC priced a $6 billion bond offering on Tuesday, joining the many companies issuing record levels of debt during the pandemic. The company, a buyer of biopharmaceutical royalties that went public in June, ...
Royalty Pharma started at equal weight at Morgan Stanley
Royalty Pharma started at neutral with $50 stock price target at J.P. Morgan
Stocks That Hit 52-Week Lows On Thursday
on Benzinga.com
Goldman Sachs Sticks to Its Buy Rating for Royalty Pharma (RPRX)
on TipRanks.com
Andreas Halvorsen's Firm Ups Inhibrx Stake
Andreas Halvorsen's Firm Ups Inhibrx Stake
on GuruFocus.com
Goldman Sachs Keeps Their Buy Rating on Royalty Pharma (RPRX)
on TipRanks.com
Earnings Scheduled For August 8, 2023
on Benzinga.com
Royalty Pharma (RPRX) Receives a Buy from Goldman Sachs
on TipRanks.com
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
on Motley Fool
Royalty Pharma CEO Trades Company's Stock
on Benzinga.com
Andreas Halvorsen Curbs Roivant Sciences Stake
Andreas Halvorsen Curbs Roivant Sciences Stake
on GuruFocus.com
Andreas Halvorsen's Firm Curbs Roivant Sciences Stake
Andreas Halvorsen's Firm Curbs Roivant Sciences Stake
on GuruFocus.com
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Johnson & Johnson | $380.49B | |
| Pfizer Inc. | $194.05B | |
| AbbVie Inc. | $257.01B | |
| Merck & Co. Inc. | $270.22B | |
| Novartis AG | CHF173.84B | |
| Gilead Sciences Inc. | $92.5B | |
| Vertex Pharmaceuticals Inc. | $88.87B | |
| Biogen Inc. | $38.19B |